[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,62,84,106,126,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100626986","epro-diary---hdv--macroliver--100626986",false,"NCT07442760","ePro Diary - HDV ( MACROLIVER )","The Patient is the Main Protagonist of His Care Journey","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of Delta infection (anti-HDV positivity)\n* Signed informed consent\n* Ability to adequately understand instructions for correctly using mobile device applications.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.","ALL","18 Years",{"count":19,"type":20},55,"ESTIMATED","OBSERVATIONAL","This study is part of the MACROLIVER Project, which aims to develop a digital tool for patients and their caregivers to manage liver diseases. Approximately 20-25 million individuals worldwide carry HBsAg and are co-infected with HDV, though geographic variations exist. In Italy, an estimated 10,000-20,000 individuals are affected by Delta hepatitis (HD). These data are approximate, given the absence of current population studies and effective screening methods.\n\nAlthough considered rare, chronic HD (CHD) is the most aggressive form of viral hepatitis, with most patients progressing rapidly to end-stage liver disease or developing hepatocellular carcinoma at a young age, often requiring liver transplantation. Screening HBsAg-positive patients for Delta co-infection is not widespread, leading to late diagnoses. Additionally, accurate quantification of viral RNA is limited to a few specialized centers.\n\nThe lack of effective antiviral therapies has led many Delta hepatitis patients to frequently switch hepatology centers in search of treatments or to miss regular medical check-ups. However, HDV management may change significantly following the recent EMA approval of a new antiviral drug, bulevirtide-an entry inhibitor administered subcutaneously daily-reimbursed in Italy since April 2023. This drug has shown promising results in Phase II and III studies, including in cirrhotic patients with severe portal hypertension.\n\nThe COVID-19 pandemic exacerbated this situation, causing reduced access to healthcare facilities and negatively impacting patients with chronic diseases. However, it also accelerated the search for effective, high-quality digital solutions for patient management.\n\nThe ePro-Diary HDV proposes to facilitate continuous communication between patients and doctors, monitor key lab values, quality of life questionnaires, and overall health status by an application for mobile phone.\n\nThe objectives are twofold: to make patients active participants in their care-enhancing retention and adherence through an \"active App-based approach\"-and to evaluate changes in patient quality of life with this \"active\" remote approach. This tool will support clinicians and patients without replacing standard clinical monitoring.",[24,25,26],"HDV","HDV Infection","Hepatitis","RECRUITING","2026-02-24",{"date":30,"type":31},"2026-03-02","ACTUAL",{"date":33,"type":31},"2025-03-31",{"date":35,"type":20},"2030-03-31",{"name":37,"class":38},"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":39},"100542414","transitional-epro-diary-liver-transitional-epro-100542414","NCT06342557","Transitional ePRO Diary Liver (Transitional-ePRO)","Integrated System for Patients Who Belong the Transition to Adult Services and Are Undergoing a Liver Transplant","MACROLIVER","Inclusion Criteria:\n\n* patients between the ages of 14 and 20 who have been transplanted at the ASST-PG23 transplant center or are awaiting a liver transplant and belong to the transition to adult services\n* signed informed consent\n* proven use of the APPs (to be assessed based on the last 2 weeks)\n\nExclusion Criteria:\n\n\\-","14 Years","20 Years",{"count":51,"type":20},250,"The study is part of the MACROLIVER Project, whose main objective is to create a digital tool for patients and caregivers for the management of liver disease that allows the optimization of therapy and\u002For the treatment process, even remotely. Such a tool not only reduces the movement of patients who are by definition fragile, but also enables the optimization of access and care by a multidisciplinary team. This tool is intended to support doctors and patients, but in no way replaces normal clinical practice. This study aims to explore the specificities of patients experiencing the transition from the pediatric ward to the adult ward in order to identify risk and protective factors that influence psychological well-being at both an individual and relational level. In order to gather all the information about the patients attending the transitional clinic and to obtain a more complete and truthful clinical-psychological picture, the study also includes the collection of retrospective data of the transplanted patients.",[54],"Liver Transplant",{"date":56,"type":31},"2026-02-27",{"date":58,"type":31},"2024-03-28",{"date":60,"type":20},"2034-02-21",{"name":37,"class":38},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},"100617314","referral-attivo-delta-dallo-screening-alla-presa-in-carico-100617314","NCT07317011","\"Referral Attivo\" Delta, Dallo Screening Alla Presa in Carico.","HDV-Reflex","Inclusion Criteria:\n\n* Patients aged ≥18 years.\n* Hospitalized at the Department of Medicine of ASST Papa Giovanni XXIII in Bergamo, or attending the SerD or the Penitentiary Health Service of Bergamo.\n* HBsAg positivity.\n* Obtaining informed consent.\n\nExclusion Criteria:\n\n* Lack of informed consent","100 Years",{"count":71,"type":20},244,"The aim of the \"Active Delta Referral\" Project is to estimate the prevalence of anti-HDV positivity among HBsAg-positive patients hospitalized in the Department of Medicine at ASST Papa Giovanni XXIII in Bergamo, as well as among patients at the SerD and the Prison Healthcare Unit of the same ASST, following the introduction of the new methodology in 2025, and to compare these findings with existing estimates for outpatients.",[74],"Hepatitis, Delta","2025-12-19",{"date":77,"type":31},"2026-01-05",{"date":79,"type":31},"2025-10-01",{"date":81,"type":20},"2026-12-31",{"name":37,"class":38},3,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":92,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100608608","a-eln-multicenter-study-on-phenotypic-evolution-and-clinical-outcomes-100608608","NCT07203768","A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes","Unmasking Polycythemia Vera in Long-Standing Essential Thrombocythemia: A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes","ET2PV","Inclusion Criteria:\n\n\\- ET patients (diagnosed according to \"International consensus classification of myeloid neoplasms and acute leukemias - 2022\" criteria) who are JAK2V617F positive and have progressed to PV (diagnosed according to \"International consensus classification of myeloid neoplasms and acute leukemias - 2022\" criteria) by 31\u002F12\u002F2020. The date of PV diagnosis will be defined as the index date and this group of patients will be defined as ET-to-PV cases.\n\nExclusion Criteria:\n\n* None.",{"count":93,"type":20},678,"International multicenter retrospective observational study consisting of two parts: a nested case-control study (part A) and a comparative retrospective cohort study (part B).",[96,97],"Polycythemia Vera","Thrombocythemia",{"date":99,"type":31},"2025-12-26",{"date":101,"type":31},"2025-12-01",{"date":103,"type":20},"2026-07-31",{"name":37,"class":38},25,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":113,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100573950","low-pv-continuation-100573950","NCT06752941","LOW-PV Continuation","CONT-LOW-PV","Inclusion Criteria:\n\n* Patients enrolled in the LOW-PV RCT study who continued to receive Ropeginterferon alfa-2b until the conclusion of the study on March 31, 2023. These patients will be included regardless of the treatment they are undergoing at the time of enrollment in the current study.\n* Patients who have signed the written informed consent for study participation.\n\nExclusion Criteria:\n\n* None",{"count":114,"type":20},36,"This multicenter longitudinal observational study focuses on Italian patients with Polycythemia Vera (PV) who were enrolled in the Low-PV RCT and continued receiving Ropeginterferon alfa-2b until the study's conclusion on March 31, 2023. It includes patients who were responders to Ropeginterferon alfa-2b after two years in the phase II randomized trial \"LOW-PV.\" Data will be collected retrospectively every 6 months from March 31, 2023 to November 30, 2024 and prospectively from December 1, 2024 to March 31, 2026.",[96],[118],"Ropeginterferon alfa-2b",{"date":99,"type":31},{"date":121,"type":31},"2024-11-30",{"date":123,"type":20},"2026-03-31",{"name":37,"class":38},13,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":114},"100557107","clinical-epidemiology-in-contemporary-patients-with-myelofibrosis-100557107","NCT06533813","Clinical Epidemiology in Contemporary Patients With Myelofibrosis.","Clinical Epidemiology in Contemporary Patients With Myelofibrosis (ERNEST-3): A European LeukemiaNet (ELN) Observational Study","ERNEST-3","Inclusion Criteria:\n\n* Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET\u002FPV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01\u002F01\u002F2018 and 31\u002F12\u002F2027\n* Age ≥ 18 years\n* Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives\n\nExclusion Criteria:\n\n* Diagnosis of early\u002Fprefibrotic primary myelofibrosis\n* Concurrent participation to interventional clinical trials in MF",{"count":135,"type":20},617,"Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01\u002F01\u002F2018 to 31\u002F12\u002F2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31\u002F12\u002F2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.",[138],"Myelofibrosis",{"date":99,"type":31},{"date":141,"type":31},"2024-10-14",{"date":143,"type":20},"2028-12-31",{"name":37,"class":38},{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100564246","clonal-hematopoiesis-of-indeterminate-potential-in-heart-failure-100564246","NCT06626685","Clonal Hematopoiesis of Indeterminate Potential in Heart Failure.","Clonal Hematopoiesis of Indeterminate Potential in Heart Failure - RICO-HF.","RICO-HF","Inclusion Criteria:\n\n* consecutive patients admitted to the Cardiology Unit of the ASST Papa Giovanni XXIII Hospital, Bergamo for acute HF and patients attending the outpatient HF clinic of the same hospital for chronic HF\n* age \\>18 years\n* written informed consent\n\nExclusion Criteria:\n\n* chronic therapy with anti-inflammatories, steroids, immunomodulators, immunosuppressants, chemotherapeuthic agents\n* previous heart transplant\n* cardiogenic shock or cardiac arrest\n* recent acute coronary syndrome (\\\u003C3 months)\n* current acute infection requiring specific treatment\n* overt MPNs\n* primary myelodysplastic syndromes\n* malignant cancers\n* non-cardiovascular co-morbidity reducing life expectancy to \\\u003C 1 year\n* any factor precluding 1-year follow-up",{"count":154,"type":20},300,"This study is part of the Rico Macro-Project, a multidisciplinary research program promoted by FROM in collaboration with the ASST-PG23 and ATS Bergamo, aiming to investigate the role of clonal hematopoiesis on inflammation, studying in depth the mechanisms underlying the inflammatory process to determine their correlation with some important pathologies in different clinical fields (Hematology, Cardiology, Neurology, Pneumology, Gastroenterology, and Diabetology, etc.). In this context, the prospective observational study RICO-HF is developed.\n\nThe RICO HF is the first project focused on CHIP and inflammation in the area of Cardiology, specifically in HF.",[157],"Heart Failure","2025-05-26",{"date":160,"type":31},"2025-05-30",{"date":162,"type":31},"2025-03-10",{"date":164,"type":20},"2027-12-31",{"name":37,"class":38},2,""]